ACCESS Newswire

Re:NewCell AB (publ)

5.11.2021 08:31:39 CET | ACCESS Newswire | Press release

Share
Interim Report Q3 2021

STOCKHOLM, SE / ACCESSWIRE / November 05, 2021 / Re:NewCell AB (publ) (FRA:6QP) (STO:RENEW)

Establishment in Sundsvall according to plan - moving from preparations into construction and mounting of equipment

July - September

Financial information

  • Net sales for the period amounted to SEK 636 thousand (328).
  • The loss after financial items amounted to SEK -24,538 thousand (-15,877).
  • Cash flow from operating activities amounted to SEK -31,567 thousand (-13,529).
  • Cash flow from investing activities was SEK -131,039 thousand (-371).
  • Earnings per share, before and after dilution, amounted to SEK -0.8 (-0.8).
  • The net cash position equaled SEK 425,842 thousand (17,379).

Significant events during the interim period

  • On July 2, Renewcell received an approved environmental permit for the planned operations in Ortviken in Sundsvall. The permit is valid with immediate effect.
  • On September 3, the Extraordinary General Meeting approved the Board's proposal to establish a warrantbased incentive program for key personnel and to enter into a loan agreement with the European Investment Bank (EIB).

January-September

Financial information

  • Net sales for the period amounted to SEK 1,465 thousand (1,221).
  • The loss after financial items amounted to SEK -67,205 thousand (-47,651).
  • Cash flow from operating activities amounted to SEK -64,985 thousand (-38,903).
  • Cash flow from investing activities was SEK -218,934 thousand (-704).
  • Earnings per share, before and after dilution, amounted to SEK -2.1 (-2.5).

Significant events after the interim period

  • On October 12, Levi's® announced that it will launch a version of its iconic 501® jeans partially made with Circulose®.
  • On October 19, Renewcell signed a letter of intent with Kelheim Fibers GmbH on anual sales of up to 10 000 tonnes Circulose®.
  • During October, the Company received the first loan disbursements corresponding to approximately SEK 320 million.

CEO's comments

Establishment in Ortviken according to plan - moving from preparations into construction and mounting of equipment.
The work with the establishment in Ortviken has now entered a new phase, meaning that Renewcell's new operations in Ortviken is beginning to take physical shape. At the beginning of the quarter the old Paper machine 5 (PM5) removed and the machine hall mostly empty. Since then, we have carried out preparatory work as planned, such as demolition of unusable installations and later piling and casting of foundations for the machines to be installed. We are happy to conclude that Ortviken has once again proved to provide excellent conditions for the establishment of Renewcell's operations as problems with basic civil work often means costly delays for companies in new establishments. We have continued our investments in machinery, equipment and organization during the quarter. For the most part, we have been able to manage the general cost increases for building materials by changing to more cost-effective materials in places where appropriate. Despite the fact that costs have increased slightly, we are still in a good position in relation to our budget. The project has so far not been affected either by the supply shortage because our larger orders were placed before the disturbances struck with greater force during the summer and late summer. So far, the global imbalance in commodity flows have not affected us. Nevertheless, our major logistics flows will start around Q2 2022, so we will follow the development for container shipping prices carefully. All in all, we therefore still have so far seen no reason to change our financial planning.

The market's interest in Circulose® remains strong. After planned test runs and optimization work as well as a summer break at the facility in Kristinehamn, we got off to a strong start during the third quarter and are well in phase in relation to our goals regarding availability and quality. We continue to sell industrial quantities to customers for both commercial fiber production and testing.

In line with our "pull strategy" in the value chain, we have during the period worked intensively with both existing and new brand partners. With the relatively low supply of Circulose® at present, it is a matter of allocating existing volume to pilot collections and quality tests, and at the same time deepening conversations about how we can help brand partners achieve their stated goals of becoming sustainable during this decade.

World leaders will soon gather in Glasgow for the delayed COP26 climate summit. In the words of the IPCC, it is now code red humanity and the 1.5-degree target may soon be out of reach. Sustainability is probably the strongest macro trend right now, and which is even stronger than digitalisation. There are few heads of state or company leaders who do not put sustainability extremely high on the agenda. We are confident that humanity has the opportunity to solve the climate crisis. Renewcell's message is that the situation is serious, but that with boldness, innovation and hard work we can actually build a long-term sustainable world. Here, Renewcell is well positioned for many years of development to create a sustainable textile and fashion industry

Stockholm, November 2021
Patrik Lundström - CEO

Contacts

Patrik Lundström
CEO
patrik.lundstrom@renewcell.com
+46 76 183 47 17

Hugo Petit
CFO
hugo.petit@renewcell.com
+46 70 7787196

About Renewcell

Founded by innovators from Stockholm's KTH Royal Institute of Technology in 2012, Re:NewCell AB (publ) (‘Renewcell') is a multi-award-winning sustaintech company based in Sweden. The company's vision is to inspire an Industrial Evolution to a sustainable world by producing high quality materials from recycled textiles.

Through its patented process, Renewcell is able to upcycle cellulosic textile waste, such as cotton clothes, transforming it into a pristine new material called Circulose®. Fast Company named Renewcell one of the World's Most Innovative Companies 2021. Circulose® was also included on TIME Magazine's list of the 100 Best Inventions 2020.

Renewcell is a publicly listed company with shares traded on Nasdaq First North Premier Growth Market with the ticker name RENEW and ISIN code SE0014960431. FNCA Sweden AB is Renewcell's Certified Adviser, +46(0)8-528 00 399, info@fnca.se .

This information is information that Re:NewCell AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-05 08:00 CET.

Attachments

Interim Report Q3 2021 Renewcell
Q3 Interim Report Renewcell Presentation 211105

SOURCE: Re:NewCell AB (publ)



View source version on accesswire.com:
https://www.accesswire.com/671345/Interim-Report-Q3-2021

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Proxymity Unveils MiKaDiv Compliance Solution for Issuers Ahead of New German Tax Regime18.11.2026 08:30:00 CET | Press release

FRANKFURT AM MAIN, DE / ACCESS Newswire / November 18, 2026 / Proxymity, the digital investor communications platform, is set to launch its MiKaDiv Compliance Solution as Germany's new dividend reporting regime takes effect in January 2027, giving German issuers a single place to manage their new obligations to the Federal Central Tax Office (BZSt). From 1 January 2027, dividends paid by listed German companies will carry an additional reporting step: the company must pass details of its shareholders to the BZSt. SRD II, transposed into German law under Section 67d of the German Stock Corporation Act, (AktG) took effect in 2020 and gave issuers the right to identify their investors, including foreign investors held through nominee accounts. MiKaDiv now makes it a requirement. The first reports are expected early in the 2027 AGM season, as issuers seek approval for their dividends. Proxymity is the leading provider of shareholder identification to German issuers, handling more than 40%

QorusDocs Named LegalTech AI Platform of the Year and Ranked No. 1 Proposal Management Software17.11.2026 15:00:00 CET | Press release

BELLEVUE, WA / ACCESS Newswire / November 17, 2026 / QorusDocs, the pursuit intelligence platform trusted by dozens of Am Law 200 and Global 200 law firms, today announced it has been named LegalTech AI Platform of the Year in the seventh annual LegalTech Breakthrough Awards program and ranked the No. 1 proposal management solution by Info-Tech Research Group's SoftwareReviews, based on verified end-user reviews. The recognitions cap a year of rapid growth in legal for QorusDocs, which forecasts it will double its annual recurring revenue (ARR) from law firms in the next 12 months by adding more high-profile firms to its list of big law customers, which already includes DLA Piper, Baker McKenzie, Herbert Smith Freehills Kramer and Womble Bond Dickinson. Firms are moving AI beyond research and drafting and into business development, where a winning pitch depends on the best representative matters, strong attorney biographies and winning pitch strategies: knowledge general AI tools lack.

Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities17.11.2026 14:00:00 CET | Press release

CORTONA, IT / ACCESS Newswire / November 17, 2026 / Freezz Italia has been awarded a contract by the European Space Agency (ESA), as prime contractor leading a European industrial consortium, for the Consolidation Phase of the IRIS² Low-LEO Pre-Operational and De-Risk Activities, part of the ESA Programme Related to EU Secure Connectivity. The activity will further mature Friisat, Freezz's satellite system architecture conceived specifically for operation in Very Low Earth Orbit (VLEO) and designed for future broadband Direct-to-Device (D2D) connectivity within the 3GPP 5G/6G Non-Terrestrial Network (NTN) framework. Under this ESA contract, Freezz Italia will consolidate the mission and system architecture, adapting Friisat's existing commercial design to meet the requirements of an IRIS²-compatible solution, including future governmental broadband Direct-To-Device secure-connectivity services. The work will address the system and service concepts, architecture and interfaces, security

International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital17.11.2026 11:00:00 CET | Press release

PARIS, FR / ACCESS Newswire / November 17, 2026 / Opti Digital, the leading AdTech company specialising in publisher revenue optimisation, today announced the results of its collaboration with International Business Times UK, an international digital news brand delivering business, markets, technology and current affairs coverage to a global readership. Operating in a fast-moving news environment, International Business Times UK continuously explores opportunities to increase the value of its digital audience while maintaining control over advertising quality and user experience. The publisher identified an opportunity to generate incremental revenue from its existing audience and inventory through a monetisation experience that could be tested progressively and scaled across a broader share of its inventory. "We were looking for ways to generate more value from our existing inventory, and the performance quickly demonstrated the potential of the new experience. It has become a meaning

OBI Pharma Signs Collaboration and License Agreement with Novartis16.11.2026 09:10:00 CET | Press release

TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes. This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye